August 31, 2015
Seikagaku Corporation said on August 28 that it has ceased the development of the small molecular compound adenosine A3 receptor agonist (development code: SI-615), which was licensed from the Israeli bioventure Can-Fite BioPharma, and has terminated a license deal. Seikagaku...read more